[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"blog-post-nisotirostide-ly3457263-en":3},{"_path":4,"_dir":5,"_draft":6,"_partial":6,"_locale":7,"title":8,"description":9,"cat":10,"icon":11,"accent":12,"date":13,"dateLabel":14,"read":15,"author":16,"image":17,"body":18,"_type":1292,"_id":1293,"_source":1294,"_file":1295,"_stem":1296,"_extension":1297},"\u002Fblog\u002Fen\u002Fnisotirostide-ly3457263","en",false,"","Nisotirostide (LY3457263): the PYY drug that only exists as a stack — and what the data actually shows","This is general education, not medical advice, and not a suggestion to obtain or take anything. Nisotirostide is an investigational drug, approved nowhere, and neither legally purchasable nor prescribable. We give no doses — none have been published, and there is a reason for that, covered below. The numbers here come from separate trials with different participants and durations; none of it is a head-to-head comparison.","Research","tabler:flask-2","#2E9E8F","2026-08-05","August 2026","12 min","myPeptides Team","\u002Fassets\u002Fnisotirostide_hero.png",{"type":19,"children":20,"toc":1279},"root",[21,28,48,53,60,79,117,135,147,153,158,327,346,351,356,362,371,398,417,422,434,440,445,457,474,491,496,568,573,592,604,609,615,626,657,667,767,779,784,789,1013,1018,1024,1029,1039,1049,1069,1075,1087,1092,1098,1127,1133,1138,1144],{"type":22,"tag":23,"props":24,"children":25},"element","p",{},[26],{"type":27,"value":9},"text",{"type":22,"tag":23,"props":29,"children":30},{},[31,33,39,41,46],{"type":27,"value":32},"A new name has been circulating in the forums for a few months now, almost always in the same phrasing: ",{"type":22,"tag":34,"props":35,"children":36},"strong",{},[37],{"type":27,"value":38},"nisotirostide",{"type":27,"value":40},", \"the thing you add on top of tirzepatide or semaglutide\". The code is ",{"type":22,"tag":34,"props":42,"children":43},{},[44],{"type":27,"value":45},"LY3457263",{"type":27,"value":47},", the company is Eli Lilly, and unlike most grey-market novelties, part of that story is genuinely true. This molecule really is built as an add-on. There is not one trial in which it was tested alone against placebo in obesity — the combination isn't the biohacker's interpretation, it's the trial design.",{"type":22,"tag":23,"props":49,"children":50},{},[51],{"type":27,"value":52},"Except that the same research turns up an awkward second finding, and it belongs in this article every bit as much as the first one.",{"type":22,"tag":54,"props":55,"children":57},"h2",{"id":56},"what-nisotirostide-actually-is",[58],{"type":27,"value":59},"What nisotirostide actually is",{"type":22,"tag":23,"props":61,"children":62},{},[63,65,70,72,77],{"type":27,"value":64},"Nisotirostide is a ",{"type":22,"tag":34,"props":66,"children":67},{},[68],{"type":27,"value":69},"synthetic peptide that activates the Y2 receptor",{"type":27,"value":71}," (also written NPY2R) — in other words, a long-acting analogue of ",{"type":22,"tag":34,"props":73,"children":74},{},[75],{"type":27,"value":76},"PYY",{"type":27,"value":78},". It is injected under the skin once a week.",{"type":22,"tag":23,"props":80,"children":81},{},[82,84,90,92,101,103,109,111,115],{"type":27,"value":83},"PYY is one of your body's own satiety signals. The L-cells in the lower small intestine and colon release it after a meal — alongside GLP-1, from the very same cells. Once in circulation, the released PYY",{"type":22,"tag":85,"props":86,"children":87},"sub",{},[88],{"type":27,"value":89},"1-36",{"type":27,"value":91}," gets trimmed to the shorter ",{"type":22,"tag":34,"props":93,"children":94},{},[95,96],{"type":27,"value":76},{"type":22,"tag":85,"props":97,"children":98},{},[99],{"type":27,"value":100},"3-36",{"type":27,"value":102},", and that trim changes the address label. The long form also binds Y1 and Y5, receptors that ",{"type":22,"tag":104,"props":105,"children":106},"em",{},[107],{"type":27,"value":108},"stimulate",{"type":27,"value":110}," appetite; PYY",{"type":22,"tag":85,"props":112,"children":113},{},[114],{"type":27,"value":100},{"type":27,"value":116}," hits Y2 almost exclusively — and Y2 turns hunger down. That is why obesity research only ever cares about the short form.",{"type":22,"tag":23,"props":118,"children":119},{},[120,122,126,128,133],{"type":27,"value":121},"Two things kept it from becoming a drug. Native PYY",{"type":22,"tag":85,"props":123,"children":124},{},[125],{"type":27,"value":100},{"type":27,"value":127}," has a half-life of roughly ",{"type":22,"tag":34,"props":129,"children":130},{},[131],{"type":27,"value":132},"10 minutes",{"type":27,"value":134},", and at the doses that produce noticeable satiety it produces nausea. You could hardly design a narrower therapeutic window. The entire modern class of PYY analogues — nisotirostide included — is an attempt to widen it: re-engineer the peptide so it lasts days instead of minutes, and make it as precisely Y2-selective as possible so you don't accidentally hit the appetite-stimulating relatives.",{"type":22,"tag":23,"props":136,"children":137},{},[138,140,145],{"type":27,"value":139},"Worth keeping straight: this is ",{"type":22,"tag":34,"props":141,"children":142},{},[143],{"type":27,"value":144},"not an incretin",{"type":27,"value":146},". Nisotirostide is not a GLP-1, not a GIP, not a glucagon agonist. It's an entirely different lever — which is exactly why it makes an interesting combination partner in the first place. Stacking two GLP-1s just hits the same receptor twice. Putting a Y2 agonist next to a GLP-1 opens a second pathway.",{"type":22,"tag":54,"props":148,"children":150},{"id":149},"the-point-where-most-write-ups-stop",[151],{"type":27,"value":152},"The point where most write-ups stop",{"type":22,"tag":23,"props":154,"children":155},{},[156],{"type":27,"value":157},"Look at the actual trial record and a remarkably clear pattern shows up. This is the complete public clinical programme for LY3457263:",{"type":22,"tag":159,"props":160,"children":161},"table",{},[162,196],{"type":22,"tag":163,"props":164,"children":165},"thead",{},[166],{"type":22,"tag":167,"props":168,"children":169},"tr",{},[170,176,181,186,191],{"type":22,"tag":171,"props":172,"children":173},"th",{},[174],{"type":27,"value":175},"Trial",{"type":22,"tag":171,"props":177,"children":178},{},[179],{"type":27,"value":180},"Phase",{"type":22,"tag":171,"props":182,"children":183},{},[184],{"type":27,"value":185},"Population",{"type":22,"tag":171,"props":187,"children":188},{},[189],{"type":27,"value":190},"What was tested",{"type":22,"tag":171,"props":192,"children":193},{},[194],{"type":27,"value":195},"Status",{"type":22,"tag":197,"props":198,"children":199},"tbody",{},[200,234,266,296],{"type":22,"tag":167,"props":201,"children":202},{},[203,209,214,219,229],{"type":22,"tag":204,"props":205,"children":206},"td",{},[207],{"type":27,"value":208},"NCT04641312",{"type":22,"tag":204,"props":210,"children":211},{},[212],{"type":27,"value":213},"1",{"type":22,"tag":204,"props":215,"children":216},{},[217],{"type":27,"value":218},"Healthy + type 2 diabetes, n = 67",{"type":22,"tag":204,"props":220,"children":221},{},[222,224],{"type":27,"value":223},"Single doses, alone ",{"type":22,"tag":34,"props":225,"children":226},{},[227],{"type":27,"value":228},"and with dulaglutide",{"type":22,"tag":204,"props":230,"children":231},{},[232],{"type":27,"value":233},"completed 12\u002F2021",{"type":22,"tag":167,"props":235,"children":236},{},[237,242,246,251,261],{"type":22,"tag":204,"props":238,"children":239},{},[240],{"type":27,"value":241},"NCT05377333",{"type":22,"tag":204,"props":243,"children":244},{},[245],{"type":27,"value":213},{"type":22,"tag":204,"props":247,"children":248},{},[249],{"type":27,"value":250},"Type 2 diabetes, n = 94",{"type":22,"tag":204,"props":252,"children":253},{},[254,256],{"type":27,"value":255},"Multiple doses, alone ",{"type":22,"tag":34,"props":257,"children":258},{},[259],{"type":27,"value":260},"and with a GLP‑1 RA",{"type":22,"tag":204,"props":262,"children":263},{},[264],{"type":27,"value":265},"completed 11\u002F2023",{"type":22,"tag":167,"props":267,"children":268},{},[269,274,278,283,291],{"type":22,"tag":204,"props":270,"children":271},{},[272],{"type":27,"value":273},"NCT05582096",{"type":22,"tag":204,"props":275,"children":276},{},[277],{"type":27,"value":213},{"type":22,"tag":204,"props":279,"children":280},{},[281],{"type":27,"value":282},"Overweight\u002Fobesity, n = 38",{"type":22,"tag":204,"props":284,"children":285},{},[286],{"type":22,"tag":34,"props":287,"children":288},{},[289],{"type":27,"value":290},"only in combination with tirzepatide",{"type":22,"tag":204,"props":292,"children":293},{},[294],{"type":27,"value":295},"completed 06\u002F2023",{"type":22,"tag":167,"props":297,"children":298},{},[299,304,309,314,322],{"type":22,"tag":204,"props":300,"children":301},{},[302],{"type":27,"value":303},"NCT06897475",{"type":22,"tag":204,"props":305,"children":306},{},[307],{"type":27,"value":308},"2",{"type":22,"tag":204,"props":310,"children":311},{},[312],{"type":27,"value":313},"Type 2 diabetes, n = 240",{"type":22,"tag":204,"props":315,"children":316},{},[317],{"type":22,"tag":34,"props":318,"children":319},{},[320],{"type":27,"value":321},"add-on to semaglutide or tirzepatide",{"type":22,"tag":204,"props":323,"children":324},{},[325],{"type":27,"value":326},"recruiting, ends 01\u002F2027",{"type":22,"tag":23,"props":328,"children":329},{},[330,332,339,341],{"type":27,"value":331},"Four trials, and every last one has a GLP-1 in the room. The single trial in people with obesity — NCT05582096 — tested only the combination with ",{"type":22,"tag":333,"props":334,"children":336},"a",{"href":335},"\u002Fglp1\u002Ftirzepatide",[337],{"type":27,"value":338},"tirzepatide",{"type":27,"value":340},", ran eleven weeks, enrolled 38 people, and had tolerability as its primary endpoint, not weight. ",{"type":22,"tag":34,"props":342,"children":343},{},[344],{"type":27,"value":345},"No results have ever been posted for it.",{"type":22,"tag":23,"props":347,"children":348},{},[349],{"type":27,"value":350},"That's the second finding, and it's the uncomfortable one. That obesity trial finished in June 2023. No weight-loss Phase 2 followed. What started in March 2025 was a diabetes trial. Drug databases now list the obesity indication for nisotirostide as inactive, with Phase 1 as the highest stage reached. The live development path is type 2 diabetes.",{"type":22,"tag":23,"props":352,"children":353},{},[354],{"type":27,"value":355},"Don't read more into that than it supports — companies shelve programmes for all sorts of reasons, and Lilly still shows the molecule in its metabolic-portfolio investor materials. But the picture of a \"nisotirostide weight-loss shot\" heading for market doesn't survive contact with the record.",{"type":22,"tag":54,"props":357,"children":359},{"id":358},"what-the-ongoing-trial-actually-measures",[360],{"type":27,"value":361},"What the ongoing trial actually measures",{"type":22,"tag":23,"props":363,"children":364},{},[365,369],{"type":22,"tag":34,"props":366,"children":367},{},[368],{"type":27,"value":303},{"type":27,"value":370}," is the study running right now, and it's worth reading closely, because it gets misquoted a lot.",{"type":22,"tag":23,"props":372,"children":373},{},[374,376,381,383,389,391,396],{"type":27,"value":375},"It enrols adults with ",{"type":22,"tag":34,"props":377,"children":378},{},[379],{"type":27,"value":380},"type 2 diabetes",{"type":27,"value":382},", HbA1c between 7.5% and 10.5%, BMI 27 or above, who have been stable on ",{"type":22,"tag":333,"props":384,"children":386},{"href":385},"\u002Fglp1\u002Fsemaglutide",[387],{"type":27,"value":388},"semaglutide",{"type":27,"value":390}," or tirzepatide for at least three months ",{"type":22,"tag":34,"props":392,"children":393},{},[394],{"type":27,"value":395},"and still haven't hit their blood-sugar target",{"type":27,"value":397},". Those people get weekly nisotirostide or placebo on top, at three blinded dose levels. 240 participants, double-blind, sites in the US, Canada, Germany, Poland, Puerto Rico and the UK.",{"type":22,"tag":23,"props":399,"children":400},{},[401,403,408,410,415],{"type":27,"value":402},"The ",{"type":22,"tag":34,"props":404,"children":405},{},[406],{"type":27,"value":407},"primary endpoint is HbA1c reduction at 24 weeks",{"type":27,"value":409},". Weight change is a ",{"type":22,"tag":104,"props":411,"children":412},{},[413],{"type":27,"value":414},"secondary",{"type":27,"value":416}," endpoint. That's not pedantry: trials are powered for their primary endpoint, and the entry criteria follow it too. The people selected here are people whose blood sugar is running away — not people looking to lose the most weight.",{"type":22,"tag":23,"props":418,"children":419},{},[420],{"type":27,"value":421},"As for doses: the arms are literally named \"Dose 1\", \"Dose 2\" and \"Dose 3\". The milligram figures are not public. So if someone quotes you a nisotirostide dose, they didn't get it from the trial — it isn't in there to read.",{"type":22,"tag":23,"props":423,"children":424},{},[425,427,432],{"type":27,"value":426},"The earliest possible first results come after primary completion in ",{"type":22,"tag":34,"props":428,"children":429},{},[430],{"type":27,"value":431},"December 2026",{"type":27,"value":433},"; the trial as a whole wraps in January 2027.",{"type":22,"tag":54,"props":435,"children":437},{"id":436},"what-a-pyy-analogue-in-a-stack-actually-delivers",[438],{"type":27,"value":439},"What a PYY analogue in a stack actually delivers",{"type":22,"tag":23,"props":441,"children":442},{},[443],{"type":27,"value":444},"There are no published efficacy data on nisotirostide itself. There are, however, data on the drug class — and one unusually well-documented experiment that asks precisely the question at hand: what happens when you add a weekly Y2 analogue on top of ongoing semaglutide?",{"type":22,"tag":23,"props":446,"children":447},{},[448,450,455],{"type":27,"value":449},"Novo Nordisk ran exactly that with its molecule ",{"type":22,"tag":34,"props":451,"children":452},{},[453],{"type":27,"value":454},"PYY1875",{"type":27,"value":456}," and published the whole thing in 2025, rats through Phase 2. A different molecule from nisotirostide, same principle: selective Y2 agonist, half-life around 10 days, once weekly.",{"type":22,"tag":23,"props":458,"children":459},{},[460,465,467,472],{"type":22,"tag":34,"props":461,"children":462},{},[463],{"type":27,"value":464},"In animals it looked spectacular.",{"type":27,"value":466}," Obese rats lost 12.5% of body weight on semaglutide alone — and ",{"type":22,"tag":34,"props":468,"children":469},{},[470],{"type":27,"value":471},"24.6%",{"type":27,"value":473}," on semaglutide plus PYY1875. Food intake fell from 389 g to 215 g. PYY1875 on its own, incidentally, did nothing at all; those animals gained weight. The effect existed only in combination. That is textbook synergy.",{"type":22,"tag":23,"props":475,"children":476},{},[477,482,484,489],{"type":22,"tag":34,"props":478,"children":479},{},[480],{"type":27,"value":481},"In humans, very little of it survived.",{"type":27,"value":483}," The Phase 2 design was built precisely around the stack question: 32 weeks of open-label semaglutide 2.4 mg as a run-in — during which participants lost 14.3% on average, from 102.1 kg to 87.5 kg — and only ",{"type":22,"tag":104,"props":485,"children":486},{},[487],{"type":27,"value":488},"then",{"type":27,"value":490}," randomisation to added PYY1875 or placebo, with semaglutide continuing throughout.",{"type":22,"tag":23,"props":492,"children":493},{},[494],{"type":27,"value":495},"The result after 16 further weeks:",{"type":22,"tag":159,"props":497,"children":498},{},[499,513],{"type":22,"tag":163,"props":500,"children":501},{},[502],{"type":22,"tag":167,"props":503,"children":504},{},[505,508],{"type":22,"tag":171,"props":506,"children":507},{},[],{"type":22,"tag":171,"props":509,"children":510},{},[511],{"type":27,"value":512},"Additional weight loss from week 32",{"type":22,"tag":197,"props":514,"children":515},{},[516,529,542],{"type":22,"tag":167,"props":517,"children":518},{},[519,524],{"type":22,"tag":204,"props":520,"children":521},{},[522],{"type":27,"value":523},"PYY1875 1.0 mg + semaglutide 2.4 mg",{"type":22,"tag":204,"props":525,"children":526},{},[527],{"type":27,"value":528},"−5.6%",{"type":22,"tag":167,"props":530,"children":531},{},[532,537],{"type":22,"tag":204,"props":533,"children":534},{},[535],{"type":27,"value":536},"Placebo + semaglutide 2.4 mg",{"type":22,"tag":204,"props":538,"children":539},{},[540],{"type":27,"value":541},"−3.1%",{"type":22,"tag":167,"props":543,"children":544},{},[545,553],{"type":22,"tag":204,"props":546,"children":547},{},[548],{"type":22,"tag":34,"props":549,"children":550},{},[551],{"type":27,"value":552},"Difference",{"type":22,"tag":204,"props":554,"children":555},{},[556,561,563],{"type":22,"tag":34,"props":557,"children":558},{},[559],{"type":27,"value":560},"−2.2 percentage points",{"type":27,"value":562}," (95% CI −4.2 to −0.1) — about ",{"type":22,"tag":34,"props":564,"children":565},{},[566],{"type":27,"value":567},"2.2 kg",{"type":22,"tag":23,"props":569,"children":570},{},[571],{"type":27,"value":572},"Two kilos. Statistically significant by a hair, with the lower end of the confidence interval nearly touching zero.",{"type":22,"tag":23,"props":574,"children":575},{},[576,578,583,585,590],{"type":27,"value":577},"And the price was steep. ",{"type":22,"tag":34,"props":579,"children":580},{},[581],{"type":27,"value":582},"Gastrointestinal adverse events hit 68% of the combination group",{"type":27,"value":584},", against 29% on semaglutide plus placebo. Severe events: 15% versus 4%. Discontinuations for adverse events: 21.3% versus 10.7%. Of 47 participants, only 30 ever reached the target dose, and by the end of treatment just ",{"type":22,"tag":34,"props":586,"children":587},{},[588],{"type":27,"value":589},"20 — 42.6% — were still on it",{"type":27,"value":591},".",{"type":22,"tag":23,"props":593,"children":594},{},[595,597,602],{"type":27,"value":596},"The higher dose level never even completed: ",{"type":22,"tag":34,"props":598,"children":599},{},[600],{"type":27,"value":601},"seven of eight",{"type":27,"value":603}," participants dropped out between weeks 3 and 12 with gastrointestinal side effects. The authors' verdict, in their own words: modest efficacy as an add-on to semaglutide, \"but the treatment was not well tolerated\".",{"type":22,"tag":23,"props":605,"children":606},{},[607],{"type":27,"value":608},"That isn't a footnote, it's the most informative data point in existence on this idea. It doesn't mean nisotirostide must fail — different molecule, different selectivity, different titration, and Lilly proved with tirzepatide that it takes tolerability seriously. But it shifts the burden of proof. Anyone claiming a PYY analogue is the big multiplier for your GLP-1 stack owes you an explanation of why it goes differently this time.",{"type":22,"tag":54,"props":610,"children":612},{"id":611},"the-competition-and-why-it-has-moved-elsewhere",[613],{"type":27,"value":614},"The competition — and why it has moved elsewhere",{"type":22,"tag":23,"props":616,"children":617},{},[618,620,625],{"type":27,"value":619},"While PYY was learning that lesson, a different drug class answered the \"what do you add to a GLP-1\" question rather convincingly: ",{"type":22,"tag":34,"props":621,"children":622},{},[623],{"type":27,"value":624},"amylin",{"type":27,"value":591},{"type":22,"tag":23,"props":627,"children":628},{},[629,634,636,641,643,648,650,655],{"type":22,"tag":34,"props":630,"children":631},{},[632],{"type":27,"value":633},"CagriSema",{"type":27,"value":635}," (cagrilintide + semaglutide, Novo Nordisk) is the finished proof. In the Phase 3 trial REDEFINE 1, with 3,417 adults without type 2 diabetes, participants lost ",{"type":22,"tag":34,"props":637,"children":638},{},[639],{"type":27,"value":640},"20.4%",{"type":27,"value":642}," at 68 weeks — and ",{"type":22,"tag":34,"props":644,"children":645},{},[646],{"type":27,"value":647},"22.7%",{"type":27,"value":649}," among those who stayed fully on treatment, with 40.4% losing at least a quarter of their body weight. For comparison, in the same trial: cagrilintide alone 11.5%, semaglutide alone 14.9%, placebo 3%. In REDEFINE 2, in people ",{"type":22,"tag":34,"props":651,"children":652},{},[653],{"type":27,"value":654},"with",{"type":27,"value":656}," type 2 diabetes, it was 13.7% versus 3.4% on placebo, and 74% reached an HbA1c of 6.5% or below.",{"type":22,"tag":23,"props":658,"children":659},{},[660,665],{"type":22,"tag":34,"props":661,"children":662},{},[663],{"type":27,"value":664},"Eloralintide",{"type":27,"value":666}," (LY3841136) is Lilly's own amylin — and the numbers explain where the attention inside the company is going. From the 48-week Phase 2 in 263 adults without diabetes, reported in November 2025:",{"type":22,"tag":159,"props":668,"children":669},{},[670,686],{"type":22,"tag":163,"props":671,"children":672},{},[673],{"type":22,"tag":167,"props":674,"children":675},{},[676,681],{"type":22,"tag":171,"props":677,"children":678},{},[679],{"type":27,"value":680},"Eloralintide, weekly",{"type":22,"tag":171,"props":682,"children":683},{},[684],{"type":27,"value":685},"Weight loss at 48 weeks",{"type":22,"tag":197,"props":687,"children":688},{},[689,702,715,728,741,754],{"type":22,"tag":167,"props":690,"children":691},{},[692,697],{"type":22,"tag":204,"props":693,"children":694},{},[695],{"type":27,"value":696},"1 mg",{"type":22,"tag":204,"props":698,"children":699},{},[700],{"type":27,"value":701},"−9.5%",{"type":22,"tag":167,"props":703,"children":704},{},[705,710],{"type":22,"tag":204,"props":706,"children":707},{},[708],{"type":27,"value":709},"3 mg",{"type":22,"tag":204,"props":711,"children":712},{},[713],{"type":27,"value":714},"−12.4%",{"type":22,"tag":167,"props":716,"children":717},{},[718,723],{"type":22,"tag":204,"props":719,"children":720},{},[721],{"type":27,"value":722},"6 mg",{"type":22,"tag":204,"props":724,"children":725},{},[726],{"type":27,"value":727},"−17.6%",{"type":22,"tag":167,"props":729,"children":730},{},[731,736],{"type":22,"tag":204,"props":732,"children":733},{},[734],{"type":27,"value":735},"9 mg",{"type":22,"tag":204,"props":737,"children":738},{},[739],{"type":27,"value":740},"−20.1%",{"type":22,"tag":167,"props":742,"children":743},{},[744,749],{"type":22,"tag":204,"props":745,"children":746},{},[747],{"type":27,"value":748},"6\u002F9 mg escalation",{"type":22,"tag":204,"props":750,"children":751},{},[752],{"type":27,"value":753},"−19.9%",{"type":22,"tag":167,"props":755,"children":756},{},[757,762],{"type":22,"tag":204,"props":758,"children":759},{},[760],{"type":27,"value":761},"Placebo",{"type":22,"tag":204,"props":763,"children":764},{},[765],{"type":27,"value":766},"−0.4%",{"type":22,"tag":23,"props":768,"children":769},{},[770,772,777],{"type":27,"value":771},"Twenty percent — as ",{"type":22,"tag":34,"props":773,"children":774},{},[775],{"type":27,"value":776},"monotherapy",{"type":27,"value":778},", with no incretin alongside it. And the tolerability was the genuinely notable part: mostly mild-to-moderate gastrointestinal symptoms and fatigue, on par with placebo at 1 and 3 mg, and markedly lower with slower escalation. Lilly has announced Phase 3 as a monotherapy and is testing the tirzepatide combination in parallel.",{"type":22,"tag":23,"props":780,"children":781},{},[782],{"type":27,"value":783},"Hold those two pictures side by side. A Y2 agonist added to semaglutide buys about two percentage points and makes two thirds of people sick. An amylin agonist buys twenty percentage points on its own and is well tolerated. It's no mystery where the money is going.",{"type":22,"tag":23,"props":785,"children":786},{},[787],{"type":27,"value":788},"The rest of the field, for completeness:",{"type":22,"tag":159,"props":790,"children":791},{},[792,817],{"type":22,"tag":163,"props":793,"children":794},{},[795],{"type":22,"tag":167,"props":796,"children":797},{},[798,803,808,813],{"type":22,"tag":171,"props":799,"children":800},{},[801],{"type":27,"value":802},"Drug",{"type":22,"tag":171,"props":804,"children":805},{},[806],{"type":27,"value":807},"What it is",{"type":22,"tag":171,"props":809,"children":810},{},[811],{"type":27,"value":812},"Best result in its own trial",{"type":22,"tag":171,"props":814,"children":815},{},[816],{"type":27,"value":195},{"type":22,"tag":197,"props":818,"children":819},{},[820,845,870,896,922,948,978],{"type":22,"tag":167,"props":821,"children":822},{},[823,830,835,840],{"type":22,"tag":204,"props":824,"children":825},{},[826],{"type":22,"tag":34,"props":827,"children":828},{},[829],{"type":27,"value":633},{"type":22,"tag":204,"props":831,"children":832},{},[833],{"type":27,"value":834},"amylin + GLP‑1 (Novo)",{"type":22,"tag":204,"props":836,"children":837},{},[838],{"type":27,"value":839},"22.7% at 68 wks",{"type":22,"tag":204,"props":841,"children":842},{},[843],{"type":27,"value":844},"Phase 3 complete",{"type":22,"tag":167,"props":846,"children":847},{},[848,855,860,865],{"type":22,"tag":204,"props":849,"children":850},{},[851],{"type":22,"tag":34,"props":852,"children":853},{},[854],{"type":27,"value":664},{"type":22,"tag":204,"props":856,"children":857},{},[858],{"type":27,"value":859},"selective amylin (Lilly)",{"type":22,"tag":204,"props":861,"children":862},{},[863],{"type":27,"value":864},"20.1% at 48 wks, alone",{"type":22,"tag":204,"props":866,"children":867},{},[868],{"type":27,"value":869},"Phase 3 starting",{"type":22,"tag":167,"props":871,"children":872},{},[873,881,886,891],{"type":22,"tag":204,"props":874,"children":875},{},[876],{"type":22,"tag":34,"props":877,"children":878},{},[879],{"type":27,"value":880},"Petrelintide",{"type":22,"tag":204,"props":882,"children":883},{},[884],{"type":27,"value":885},"amylin (Zealand\u002FRoche)",{"type":22,"tag":204,"props":887,"children":888},{},[889],{"type":27,"value":890},"10.7% at 42 wks",{"type":22,"tag":204,"props":892,"children":893},{},[894],{"type":27,"value":895},"Phase 2 positive (03\u002F2026)",{"type":22,"tag":167,"props":897,"children":898},{},[899,907,912,917],{"type":22,"tag":204,"props":900,"children":901},{},[902],{"type":22,"tag":34,"props":903,"children":904},{},[905],{"type":27,"value":906},"Amycretin",{"type":22,"tag":204,"props":908,"children":909},{},[910],{"type":27,"value":911},"GLP‑1 + amylin in one molecule (Novo)",{"type":22,"tag":204,"props":913,"children":914},{},[915],{"type":27,"value":916},"24.3% at 36 wks",{"type":22,"tag":204,"props":918,"children":919},{},[920],{"type":27,"value":921},"Phase 1b\u002F2a",{"type":22,"tag":167,"props":923,"children":924},{},[925,933,938,943],{"type":22,"tag":204,"props":926,"children":927},{},[928],{"type":22,"tag":34,"props":929,"children":930},{},[931],{"type":27,"value":932},"MariTide",{"type":22,"tag":204,"props":934,"children":935},{},[936],{"type":27,"value":937},"GLP‑1 agonist + GIP blocker, monthly (Amgen)",{"type":22,"tag":204,"props":939,"children":940},{},[941],{"type":27,"value":942},"~20% at 52 wks",{"type":22,"tag":204,"props":944,"children":945},{},[946],{"type":27,"value":947},"Phase 2",{"type":22,"tag":167,"props":949,"children":950},{},[951,963,968,973],{"type":22,"tag":204,"props":952,"children":953},{},[954],{"type":22,"tag":34,"props":955,"children":956},{},[957],{"type":22,"tag":333,"props":958,"children":960},{"href":959},"\u002Fglp1\u002Fretatrutide",[961],{"type":27,"value":962},"Retatrutide",{"type":22,"tag":204,"props":964,"children":965},{},[966],{"type":27,"value":967},"GLP‑1 + GIP + glucagon (Lilly)",{"type":22,"tag":204,"props":969,"children":970},{},[971],{"type":27,"value":972},"~24% at 48 wks",{"type":22,"tag":204,"props":974,"children":975},{},[976],{"type":27,"value":977},"Phase 3",{"type":22,"tag":167,"props":979,"children":980},{},[981,989,997,1005],{"type":22,"tag":204,"props":982,"children":983},{},[984],{"type":22,"tag":34,"props":985,"children":986},{},[987],{"type":27,"value":988},"Nisotirostide",{"type":22,"tag":204,"props":990,"children":991},{},[992],{"type":22,"tag":34,"props":993,"children":994},{},[995],{"type":27,"value":996},"Y2\u002FPYY agonist (Lilly)",{"type":22,"tag":204,"props":998,"children":999},{},[1000],{"type":22,"tag":34,"props":1001,"children":1002},{},[1003],{"type":27,"value":1004},"none published",{"type":22,"tag":204,"props":1006,"children":1007},{},[1008],{"type":22,"tag":34,"props":1009,"children":1010},{},[1011],{"type":27,"value":1012},"Phase 2, diabetes",{"type":22,"tag":23,"props":1014,"children":1015},{},[1016],{"type":27,"value":1017},"That last row is this whole article in one line.",{"type":22,"tag":54,"props":1019,"children":1021},{"id":1020},"the-honest-answer-to-the-original-question",[1022],{"type":27,"value":1023},"The honest answer to the original question",{"type":22,"tag":23,"props":1025,"children":1026},{},[1027],{"type":27,"value":1028},"Can you think of nisotirostide as a weight-loss shot stacked on tirzepatide or semaglutide?",{"type":22,"tag":23,"props":1030,"children":1031},{},[1032,1037],{"type":22,"tag":34,"props":1033,"children":1034},{},[1035],{"type":27,"value":1036},"Conceptually: yes, and that's explicitly the design.",{"type":27,"value":1038}," It isn't an incretin, it's a separate satiety pathway, and every trial pairs it with a GLP-1 for exactly that reason. The pharmacology is sound.",{"type":22,"tag":23,"props":1040,"children":1041},{},[1042,1047],{"type":22,"tag":34,"props":1043,"children":1044},{},[1045],{"type":27,"value":1046},"Evidentially: no, at least not today.",{"type":27,"value":1048}," There are zero published efficacy numbers for the molecule. The only obesity trial was an eleven-week tolerability study in 38 people with no results posted. The live development path targets blood sugar, not weight. And the one fully published human experiment in this drug class produced about two kilos at a side-effect rate that drove one in five participants out of the study.",{"type":22,"tag":23,"props":1050,"children":1051},{},[1052,1054,1060,1062,1068],{"type":27,"value":1053},"Then there's the part that never changes: whatever is circulating as \"nisotirostide\" right now is by definition unapproved grey-market material of unknown identity and purity. An NCT number doesn't vouch for the vial someone ships you — and in this case it doesn't even vouch for a dose, because the trial doses are blinded. Our primer ",{"type":22,"tag":333,"props":1055,"children":1057},{"href":1056},"\u002Fare-peptides-legal",[1058],{"type":27,"value":1059},"Are peptides legal?",{"type":27,"value":1061}," lays out the legal picture, and if you want to start from scratch, ",{"type":22,"tag":333,"props":1063,"children":1065},{"href":1064},"\u002Fwhat-are-peptides",[1066],{"type":27,"value":1067},"what peptides are",{"type":27,"value":591},{"type":22,"tag":54,"props":1070,"children":1072},{"id":1071},"what-you-can-watch-for",[1073],{"type":27,"value":1074},"What you can watch for",{"type":22,"tag":23,"props":1076,"children":1077},{},[1078,1080,1085],{"type":27,"value":1079},"One date decides whether this story continues: ",{"type":22,"tag":34,"props":1081,"children":1082},{},[1083],{"type":27,"value":1084},"primary completion of NCT06897475 in December 2026",{"type":27,"value":1086},". That is the first time there will be numbers on the molecule itself — HbA1c primary, weight secondary, against placebo, on top of semaglutide or tirzepatide. If the weight curve moves meaningfully and dropout rates stay decent, that shelved obesity programme comes back fast. If it stays flat, or the gastrointestinal pattern repeats, the question is settled.",{"type":22,"tag":23,"props":1088,"children":1089},{},[1090],{"type":27,"value":1091},"Until then, nisotirostide is a drug to watch, not to source.",{"type":22,"tag":54,"props":1093,"children":1095},{"id":1094},"what-this-means-for-you-today",[1096],{"type":27,"value":1097},"What this means for you today",{"type":22,"tag":23,"props":1099,"children":1100},{},[1101,1103,1109,1111,1117,1119,1125],{"type":27,"value":1102},"For the compounds people actually run, the neutral part is the arithmetic. If you're tracking what you have, at what concentration, and when, ",{"type":22,"tag":333,"props":1104,"children":1106},{"href":1105},"\u002Fpeptides-list",[1107],{"type":27,"value":1108},"our peptide tracker",{"type":27,"value":1110}," is built for exactly that. If reconstitution is the shaky step, ",{"type":22,"tag":333,"props":1112,"children":1114},{"href":1113},"\u002Fcalculator",[1115],{"type":27,"value":1116},"our calculator",{"type":27,"value":1118}," turns a target dose into units on the syringe once you know the vial concentration and the bacteriostatic water you added. And because these are weekly injections whose levels rise and fall between shots, ",{"type":22,"tag":333,"props":1120,"children":1122},{"href":1121},"\u002Fplotter",[1123],{"type":27,"value":1124},"the level plotter",{"type":27,"value":1126}," draws that curve. None of it is a recommendation to take anything — it's the maths, kept honest.",{"type":22,"tag":54,"props":1128,"children":1130},{"id":1129},"bottom-line",[1131],{"type":27,"value":1132},"Bottom line",{"type":22,"tag":23,"props":1134,"children":1135},{},[1136],{"type":27,"value":1137},"Nisotirostide (LY3457263) is Lilly's once-weekly PYY analogue at the Y2 receptor, and it genuinely is engineered as a combination partner — it has never been tested any other way. That much of the forum story holds up. The rest doesn't: there are no published efficacy data, the only obesity trial was a small tolerability study with no results, active development is aimed at type 2 diabetes, and the best published experiment in the class delivered about two extra kilos alongside 68% gastrointestinal side effects. Meanwhile amylin has answered the combination question: CagriSema at 22.7%, eloralintide at 20.1% flying solo and well tolerated. If you want to see where the next generation of weight-loss drugs is heading, watch the amylins. Nisotirostide is an interesting footnote with a date in December 2026 — not an answer yet.",{"type":22,"tag":54,"props":1139,"children":1141},{"id":1140},"sources",[1142],{"type":27,"value":1143},"Sources",{"type":22,"tag":1145,"props":1146,"children":1147},"ul",{},[1148,1162,1173,1184,1195,1207,1219,1231,1243,1255,1267],{"type":22,"tag":1149,"props":1150,"children":1151},"li",{},[1152,1154],{"type":27,"value":1153},"ClinicalTrials.gov, ",{"type":22,"tag":333,"props":1155,"children":1159},{"href":1156,"rel":1157},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT06897475",[1158],"nofollow",[1160],{"type":27,"value":1161},"NCT06897475 — LY3457263 as an add-on to semaglutide or tirzepatide in type 2 diabetes (Phase 2)",{"type":22,"tag":1149,"props":1163,"children":1164},{},[1165,1166],{"type":27,"value":1153},{"type":22,"tag":333,"props":1167,"children":1170},{"href":1168,"rel":1169},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT05582096",[1158],[1171],{"type":27,"value":1172},"NCT05582096 — LY3457263 in combination with tirzepatide in overweight\u002Fobesity (Phase 1)",{"type":22,"tag":1149,"props":1174,"children":1175},{},[1176,1177],{"type":27,"value":1153},{"type":22,"tag":333,"props":1178,"children":1181},{"href":1179,"rel":1180},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT05377333",[1158],[1182],{"type":27,"value":1183},"NCT05377333 — LY3457263 alone and with a GLP-1 RA in type 2 diabetes (Phase 1)",{"type":22,"tag":1149,"props":1185,"children":1186},{},[1187,1188],{"type":27,"value":1153},{"type":22,"tag":333,"props":1189,"children":1192},{"href":1190,"rel":1191},"https:\u002F\u002Fclinicaltrials.gov\u002Fstudy\u002FNCT04641312",[1158],[1193],{"type":27,"value":1194},"NCT04641312 — first-in-human single ascending dose study (Phase 1)",{"type":22,"tag":1149,"props":1196,"children":1197},{},[1198,1200],{"type":27,"value":1199},"Wulff et al., Obesity 2025, ",{"type":22,"tag":333,"props":1201,"children":1204},{"href":1202,"rel":1203},"https:\u002F\u002Fonlinelibrary.wiley.com\u002Fdoi\u002F10.1002\u002Foby.24329",[1158],[1205],{"type":27,"value":1206},"Long-acting PYY3−36 analogue with semaglutide for obesity: from preclinical assessment through randomized clinical studies",{"type":22,"tag":1149,"props":1208,"children":1209},{},[1210,1212],{"type":27,"value":1211},"Østergaard et al., Science Translational Medicine 2025, ",{"type":22,"tag":333,"props":1213,"children":1216},{"href":1214,"rel":1215},"https:\u002F\u002Fwww.science.org\u002Fdoi\u002F10.1126\u002Fscitranslmed.adq6392",[1158],[1217],{"type":27,"value":1218},"Variant screening of PYY3–36 leads to potent long-acting PYY analogs with superior Y2 receptor selectivity",{"type":22,"tag":1149,"props":1220,"children":1221},{},[1222,1224],{"type":27,"value":1223},"Eli Lilly, ",{"type":22,"tag":333,"props":1225,"children":1228},{"href":1226,"rel":1227},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Flillys-selective-amylin-agonist-eloralintide-demonstrated-meaningful-weight-loss-and-favorable-tolerability-in-a-phase-2-study-of-adults-with-obesity-or-overweight-302607061.html",[1158],[1229],{"type":27,"value":1230},"Eloralintide: Phase 2 results for the selective amylin agonist",{"type":22,"tag":1149,"props":1232,"children":1233},{},[1234,1236],{"type":27,"value":1235},"Novo Nordisk \u002F NEJM, ",{"type":22,"tag":333,"props":1237,"children":1240},{"href":1238,"rel":1239},"https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fcagrisema-2-4-mg--2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-redefine-1--published-in-nejm-302487770.html",[1158],[1241],{"type":27,"value":1242},"CagriSema 2.4 mg\u002F2.4 mg — 22.7% mean weight reduction in REDEFINE 1",{"type":22,"tag":1149,"props":1244,"children":1245},{},[1246,1248],{"type":27,"value":1247},"NEJM 2025, ",{"type":22,"tag":333,"props":1249,"children":1252},{"href":1250,"rel":1251},"https:\u002F\u002Fwww.nejm.org\u002Fdoi\u002Fabs\u002F10.1056\u002FNEJMoa2502082",[1158],[1253],{"type":27,"value":1254},"Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2)",{"type":22,"tag":1149,"props":1256,"children":1257},{},[1258,1260],{"type":27,"value":1259},"Roche, ",{"type":22,"tag":333,"props":1261,"children":1264},{"href":1262,"rel":1263},"https:\u002F\u002Fwww.roche.com\u002Fmedia\u002Freleases\u002Fmed-cor-2026-03-05",[1158],[1265],{"type":27,"value":1266},"Positive Phase II results for the amylin analogue petrelintide",{"type":22,"tag":1149,"props":1268,"children":1269},{},[1270,1272],{"type":27,"value":1271},"Amgen, ",{"type":22,"tag":333,"props":1273,"children":1276},{"href":1274,"rel":1275},"https:\u002F\u002Fwww.amgen.com\u002Fnewsroom\u002Fpress-releases\u002F2024\u002F11\u002Famgen-announces-robust-weight-loss-with-maritide-in-people-living-with-obesity-or-overweight-at-52-weeks-in-a-phase-2-study",[1158],[1277],{"type":27,"value":1278},"Phase 2 results for MariTide at 52 weeks",{"title":7,"searchDepth":1280,"depth":1280,"links":1281},2,[1282,1283,1284,1285,1286,1287,1288,1289,1290,1291],{"id":56,"depth":1280,"text":59},{"id":149,"depth":1280,"text":152},{"id":358,"depth":1280,"text":361},{"id":436,"depth":1280,"text":439},{"id":611,"depth":1280,"text":614},{"id":1020,"depth":1280,"text":1023},{"id":1071,"depth":1280,"text":1074},{"id":1094,"depth":1280,"text":1097},{"id":1129,"depth":1280,"text":1132},{"id":1140,"depth":1280,"text":1143},"markdown","content:blog:en:nisotirostide-ly3457263.md","content","blog\u002Fen\u002Fnisotirostide-ly3457263.md","blog\u002Fen\u002Fnisotirostide-ly3457263","md"]